ERBB2 and breast cancer: Furthermore, identifying structural barriers and prescriber-specific factors associated with the overall likelihood of receiving ERBB2-targeted therapy in more recent time frames, even as guidelines broadly recommend use of these drugs, is crucial to improving quality of breast cancer care.